Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Jon C. Ogg | Mar 8, 2014 at 8:01 AM EST

Low-Priced Biotech Stocks That Could Double (or More)

ThinkstockThe latter part of the week was difficult for the biotech and specialty pharmaceutical sector. Unsettling news out of Washington,…

Jon C. Ogg | Mar 7, 2014 at 10:30 AM EST

Biomet Is Coming Public via IPO, Again

ThinkstockWhat would appear to be an obscure initial public offering from LVB Acquisition Inc. is much more important than it…

Trey Thoelcke | Mar 7, 2014 at 9:00 AM EST

Biotech Stocks to Buy After the Pullback

The biotech and specialty pharmaceutical groups got hit hard Thursday for a variety of reasons. The largest of which the…

Jon C. Ogg | Mar 6, 2014 at 3:43 PM EST

Analyst Still Sees Dendreon Worth Only $1

ThinkstockDendreon Corp. (NASDAQ: DNDN) remains a company in trouble. The post-earnings jump looked promising and investors probably took some comfort…

cgblaine22 | Mar 6, 2014 at 7:35 AM EST

Peregrine Move Looks Sustainable, at Least for Now

Peregrine Pharmaceuticals may be on the verge of something big with its anticancer drugs. The shares soared almost 50% on…

Trey Thoelcke | Mar 4, 2014 at 8:50 AM EST

Merrill Lynch’s Top Health Care Stocks to Buy Now

Merrill Lynch likes the health care sector and has made no secret that they think that it can continue to…

cgblaine22 | Mar 3, 2014 at 10:55 AM EST

Dendreon Finds New, Long Overdue Lifeblood

Shares of Dendreon moved higher Monday after the biotech company said it will start to market Provenge, its prostate-cancer drug,…

Jon C. Ogg | Mar 1, 2014 at 10:39 AM EST

Top Biotech Stocks Under $5 With Huge Potential Upside

ThinkstockWith the top stocks in the market exploding in price due to the recent rally, we wanted to scan across…

Jon C. Ogg | Feb 28, 2014 at 9:55 AM EST

A Punishing Compugen Secondary Offering to Raise Cash

Compugen is raising close to $60 million in a secondary offering, but at a punishing price to any new shareholders…

Jon C. Ogg | Feb 27, 2014 at 10:40 AM EST

Can Aegerion Still Rise 70%?

Merrill Lynch issued a note on Aegerion Pharmaceuticals in the wake of its earnings report that both maintained a Buy…

Trey Thoelcke | Feb 27, 2014 at 7:00 AM EST

Short Sellers Return to Biotech Stocks

After largely shying away in the previous period, short sellers returned to many of the leading biotech and emerging pharmaceutical…

Jon C. Ogg | Feb 26, 2014 at 3:38 PM EST

Best Performing IPOs of 2014 Are in Biotech

ThinkstockThe initial public offering market has been rather strong in 2014. After we recently featured our Top 10 IPOs to…

cgblaine22 | Feb 26, 2014 at 10:15 AM EST

Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come

Shares of biotechnology company Anika Therapeutics soared to an all-time high Wednesday after the company said the FDA had approved…

Jon C. Ogg | Feb 25, 2014 at 1:28 PM EST

VIVUS Chances of a Stock Double Shrinking

ThinkstockVIVUS Inc. (NASDAQ: VVUS) is suffering from what looked like good news on the surface. The reality, and the catch…

cgblaine22 | Feb 25, 2014 at 10:34 AM EST

InterMune Lung Treatment Brings Buyout Gains, Without a Buyout

ThinkstockShares of biotech company InterMune Inc. (NASDAQ: ITMN) more than doubled Tuesday after the company said its experimental drug pirfenidone,…

1 … 292 293 294 295 296 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Low-Priced Biotech Stocks That Could Double (or More)

Biomet Is Coming Public via IPO, Again

Biotech Stocks to Buy After the Pullback

Analyst Still Sees Dendreon Worth Only $1

Peregrine Move Looks Sustainable, at Least for Now

Merrill Lynch’s Top Health Care Stocks to Buy Now

Dendreon Finds New, Long Overdue Lifeblood

Top Biotech Stocks Under $5 With Huge Potential Upside

A Punishing Compugen Secondary Offering to Raise Cash

Can Aegerion Still Rise 70%?

Short Sellers Return to Biotech Stocks

Best Performing IPOs of 2014 Are in Biotech

Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come

VIVUS Chances of a Stock Double Shrinking

InterMune Lung Treatment Brings Buyout Gains, Without a Buyout

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

Health and Healthcare Articles

All Health and Healthcare Articles

Low-Priced Biotech Stocks That Could Double (or More)

Biomet Is Coming Public via IPO, Again

Biotech Stocks to Buy After the Pullback

Analyst Still Sees Dendreon Worth Only $1

Peregrine Move Looks Sustainable, at Least for Now

Merrill Lynch’s Top Health Care Stocks to Buy Now

Dendreon Finds New, Long Overdue Lifeblood

Top Biotech Stocks Under $5 With Huge Potential Upside

A Punishing Compugen Secondary Offering to Raise Cash

Can Aegerion Still Rise 70%?

Short Sellers Return to Biotech Stocks

Best Performing IPOs of 2014 Are in Biotech

Anika Arthritis Treatment Approval Brings All-Time Highs, Maybe More to Come

VIVUS Chances of a Stock Double Shrinking

InterMune Lung Treatment Brings Buyout Gains, Without a Buyout

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

Featured Reads

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up